Crispr Therapeutics Ag (CRSP)

Dec 21, 2024

1 Reason to Sell DexCom Stock, and 1 Reason to Buy - The Motley Fool

Dec 21, 2024

Dec 20, 2024

Intellia Crashes 60% in a Year: How Should You Play the Stock? - Yahoo Finance

Dec 20, 2024

Dec 20, 2024

CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year - Investing.com

Dec 20, 2024

Dec 20, 2024

JMP Securities Reaffirms "Market Outperform" Rating for CRISPR Therapeutics (NASDAQ:CRSP) - MarketBeat

Dec 20, 2024

Dec 19, 2024

CRISPR Therapeutics (NASDAQ:CRSP) Hits New 12-Month LowTime to Sell? - MarketBeat

Dec 19, 2024

Dec 18, 2024

3 Things You Need to Know if You Buy CRISPR Therapeutics Today - MSN

Dec 18, 2024

Dec 17, 2024

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025 - Yahoo Finance

Dec 17, 2024

Dec 16, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Sees Significant Decline in Short Interest - MarketBeat

Dec 16, 2024

Dec 15, 2024

State Street Corp Acquires 599,304 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Dec 15, 2024

Dec 14, 2024

CRISPR Therapeutics (NASDAQ:CRSP) Sets New 1-Year LowShould You Sell? - MarketBeat

Dec 14, 2024

Dec 14, 2024

3 Things You Need To Know If You Buy CRISPR Therapeutics Today - Barchart

Dec 14, 2024

Dec 13, 2024

CRISPR Therapeutics stock hits 52-week low at $43.37 - Investing.com

Dec 13, 2024

Dec 12, 2024

Zacks Research Issues Negative Forecast for CRSP Earnings - MarketBeat

Dec 12, 2024

Dec 11, 2024

Is CRISPR Therapeutics AG (CRSP) the Worst ARK Stock to Buy According to Short Sellers? - Insider Monkey

Dec 11, 2024

Dec 11, 2024

Catherine Wood's Strategic Acquisition of CRISPR Therapeutics AG Shares - GuruFocus.com

Dec 11, 2024

Dec 11, 2024

What is William Blair's Forecast for CRSP FY2024 Earnings? - MarketBeat

Dec 11, 2024

Dec 10, 2024

CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from Chardan Capital - MarketBeat

Dec 10, 2024

Dec 09, 2024

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewswire

Dec 09, 2024

Dec 09, 2024

CRISPR's CTX112 Cancer Therapy Shows 67% Response Rate in Clinical Trial, Earns FDA Special Status - StockTitan

Dec 09, 2024

Dec 09, 2024

XTX Topco Ltd Grows Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Dec 09, 2024

Dec 08, 2024

Main Management ETF Advisors LLC Purchases Shares of 14,744 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Dec 08, 2024

Dec 07, 2024

2 Biotech Stocks to Buy Hand Over Fist in December - AOL

Dec 07, 2024

Dec 06, 2024

CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Dec 06, 2024

Dec 06, 2024

Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report? - MSN

Dec 06, 2024

Dec 06, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Benjamin Edwards Inc. - MarketBeat

Dec 06, 2024

Dec 06, 2024

Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet - MSN

Dec 06, 2024

Dec 05, 2024

January 2025 Options Now Available For CRISPR Therapeutics (CRSP) - Nasdaq

Dec 05, 2024

Dec 05, 2024

Future-Proofing Growth of Gene Editing Technology Innovation - openPR

Dec 05, 2024

Dec 05, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Dec 05, 2024

Dec 05, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by BNP Paribas Financial Markets - MarketBeat

Dec 05, 2024

Dec 05, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Fmr LLC - MarketBeat

Dec 05, 2024

Dec 04, 2024

Crispr Therapeutics CEO Kulkarni sells $826,564 in shares By Investing.com - Investing.com Nigeria

Dec 04, 2024

Dec 04, 2024

Crispr Therapeutics CEO Kulkarni sells $826,564 in shares - Investing.com India

Dec 04, 2024

Dec 03, 2024

CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Rating of "Hold" from Analysts - MarketBeat

Dec 03, 2024

Dec 03, 2024

CRISPR Therapeutics: Strong Balance Sheet Supports Ambitious Plans Amid Slow Growth - Seeking Alpha

Dec 03, 2024

Dec 02, 2024

CRISPR Technology Market Growth Trends from 2024 to 2033 | Key - openPR

Dec 02, 2024

Dec 02, 2024

Baker BROS. Advisors LP Boosts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Dec 02, 2024

Nov 28, 2024

Zacks Research Has Bullish Forecast for CRSP FY2024 Earnings - MarketBeat

Nov 28, 2024

Nov 26, 2024

Loomis Sayles & Co. L P Trims Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat

Nov 26, 2024

Nov 24, 2024

Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? - Yahoo Finance

Nov 24, 2024

Nov 22, 2024

Learn to Evaluate (CRSP) using the Charts - Stock Traders Daily

Nov 22, 2024

Nov 21, 2024

Why Is CRISPR Therapeutics AG (CRSP) Among the Worst Performing Biotech Stocks in 2024? - Insider Monkey

Nov 21, 2024

Nov 20, 2024

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell? - MSN

Nov 20, 2024